Business Context and Reporting Period
Company: Altimmune, Inc. (ALT)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: Altimmune is a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases. Its lead program is pemvidutide, a dual glucagon/GLP-1 receptor agonist for MASH, Alcohol Use Disorder (AUD), and Alcohol-Associated Liver Disease (ALD). The company has not generated revenue from product sales.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenues | $5 | $5 | $15 | $15 |
| Net Loss | $(19,014) | $(22,845) | $(60,735) | $(71,879) |
| Diluted EPS | $(0.21) | $(0.32) | $(0.74) | $(1.01) |
| Operating Expenses | $20,864 | $24,772 | $65,611 | $78,321 |
| Cash & Equivalents | $61,236 | $36,926 | $61,236 | $36,926 |
| Short-term Investments | $149,540 | $94,965 | $149,540 | $94,965 |
| Total Liquidity | $210,776 | $131,891 | $210,776 | $131,891 |
| Term Loan (Noncurrent) | $14,445 | $0 | $14,445 | $0 |
Note: Liquidity includes cash, cash equivalents, restricted cash, and short-term investments.
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by 17% in Q3 2025 and 16% in the nine-month period compared to 2024, driven primarily by lower Research and Development (R&D) expenses.
- R&D Expense Reduction: R&D expenses declined 24% in Q3 and 23% in the nine-month period. This was due to the completion of enrollment in the MASH Phase 2b trial and the termination of the HepTcell program in 2024, partially offset by costs for new AUD and ALD trials.
- Increased G&A Expenses: General and administrative expenses rose 19% in Q3 and 11% in the nine-month period, attributed to higher stock-based compensation and professional service fees.
- Debt Financing: The company secured a $100 million term loan facility in May 2025, drawing the first tranche of $15 million. This introduced interest expense of $0.5 million in Q3 and $0.8 million for the nine months, compared to negligible interest in 2024.
- Capital Raising: The company raised approximately $112 million in net proceeds from at-the-market equity offerings during the nine months ended September 30, 2025.
Outlook, Risks, and Management Commentary
- Clinical Progress:
- MASH: Released positive topline results from the IMPACT Phase 2b trial showing MASH resolution in 58% and 52% of subjects at 1.2mg and 1.8mg doses, respectively, versus 20% placebo.
- AUD: Received FDA Fast Track designation. Completed enrollment in the RECLAIM Phase 2 trial ahead of schedule; topline results expected in 2026.
- ALD: Initiated the RESTORE Phase 2 trial.
- Liquidity Outlook: Management believes current cash and investment resources ($210.8 million) are sufficient to fund operations for at least 12 months from the filing date.
- Subsequent Events:
- Post-period equity raises of $33.8 million in October 2025.
- Amendment to the Term Loan facility on November 5, 2025, increasing total availability to $125 million and drawing a second tranche of $20 million.
- Risks and Contingencies:
- Litigation: A securities class action lawsuit was filed in August 2025 alleging false statements regarding pemvidutide and the IMPACT trial. A shareholder derivative suit was also filed in September 2025. The company intends to defend vigorously.
- Regulatory/Political: Potential delays due to the U.S. government shutdown and global tariff uncertainties.
- Capital Needs: Continued reliance on equity or debt financing to fund future clinical trials and operations.
Investor Verification Checklist
- Verify the status and timeline of the securities class action and derivative litigation filed in late 2025.
- Confirm the terms and covenants of the amended $125 million term loan facility with Hercules Capital.
- Monitor the progress of the RECLAIM (AUD) and RESTORE (ALD) Phase 2 trials and the anticipated 2026 topline data release.
- Assess the burn rate relative to the $210.8 million liquidity position to determine the runway for future financing needs.
- Review the impact of the "One Big Beautiful Bill Act" (OBBBA) on the company's tax position and deferred tax assets.